Medication Exposure Risks During Assisted Reproductive Cycles

Abstract

Assisted reproductive technologies (ART) have revolutionized infertility management, yet the use of various medications during these cycles introduces unique risks for both patients and potential offspring. This review critically examines the spectrum of medication exposure risks during ART, synthesizing recent evidence, mechanistic insights, and guideline recommendations to inform clinical practice. The article addresses the epidemiology of medication use in ART, the underlying pathophysiological mechanisms, risk factors, clinical features of adverse reactions, diagnostic approaches, management strategies, recent advances, and current guidelines. Clinically relevant implications for patient counseling and risk mitigation are highlighted, providing a robust foundation for evidence-based practice in reproductive medicine.

Introduction

Assisted reproductive cycles, including in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), commonly utilize a range of pharmacological agents for ovarian stimulation, ovulation induction, luteal phase support, and adjunctive therapies. While these medications enhance cycle success rates, they also pose potential risks ranging from mild adverse effects to significant maternal and fetal complications. Given the increasing global prevalence of ART, understanding medication exposure risks is imperative for optimizing outcomes and minimizing harm. This review systematically explores these risks, integrating the latest research and guideline-based recommendations to support clinical decision-making.

Epidemiology / Disease Burden

Globally, over 2.5 million ART cycles are performed annually, with pharmacological agents such as gonadotropins, GnRH analogs, and progestogens constituting the therapeutic backbone. Adverse medication events are not uncommon: ovarian hyperstimulation syndrome (OHSS) occurs in 3–8% of high-risk cycles, while thromboembolic events, hypersensitivity reactions, and teratogenic exposures are reported less frequently but can carry substantial morbidity. The widespread use of adjunctive medications, including antibiotics, anticoagulants, and immunomodulators, further compounds the risk profile, underscoring the importance of vigilance in medication management during ART cycles.

Pathophysiology

The mechanisms underpinning medication-related risks in ART are multifactorial. Gonadotropins stimulate supraphysiological estradiol levels, increasing vascular permeability and predisposing to OHSS. GnRH agonists and antagonists disrupt endogenous hormonal feedback, potentially impacting endometrial receptivity and embryonic development. Certain adjunctive medications may cross the placental barrier or alter maternal-fetal pharmacokinetics, leading to teratogenic effects or impaired implantation. Furthermore, drug-drug interactions, especially in polypharmacy settings, can exacerbate toxicity or reduce therapeutic efficacy. Understanding these mechanisms guides risk assessment and informs safer prescribing practices.

Risk Factors

Several patient- and treatment-related factors modulate medication exposure risks during ART. Young age, polycystic ovary syndrome (PCOS), high antral follicle count, and elevated anti-Müllerian hormone (AMH) levels heighten susceptibility to OHSS. Prior adverse reactions, coexisting medical conditions (e.g., thrombophilia, autoimmune disorders), and concomitant medication use (e.g., NSAIDs, anticoagulants) further amplify risk. Personalized risk stratification using clinical, biochemical, and genetic markers is increasingly advocated to tailor ART protocols and minimize adverse outcomes.

Clinical Features

Clinical manifestations of medication exposure during ART vary in severity and timing. OHSS typically presents with abdominal pain, ascites, hemoconcentration, and electrolyte imbalances within days of ovulation trigger. Hypersensitivity reactions to gonadotropins or adjunctive drugs may manifest as urticaria, angioedema, or anaphylaxis. Thromboembolic complications, though rare, can present as deep vein thrombosis or pulmonary embolism, particularly in hyperestrogenic states. Teratogenic exposures may not be clinically apparent until later gestation or postnatally, emphasizing the need for preconception counseling and early risk identification.

Diagnosis

Diagnosis of medication-related adverse events in ART is primarily clinical, supported by laboratory and imaging modalities. OHSS is graded based on clinical severity, ultrasound findings (e.g., ovarian enlargement, ascites), and laboratory parameters (hematocrit, electrolytes). Drug hypersensitivity is confirmed through clinical history, skin testing, and, in select cases, in vitro assays. Thromboembolic events necessitate Doppler ultrasonography or CT angiography. Documentation of all medications, including over-the-counter and herbal supplements, is essential for comprehensive risk assessment and differential diagnosis.

Treatment & Management

Management of medication exposure risks during ART is multifaceted, encompassing prevention, early recognition, and targeted intervention. Prophylactic strategies include individualized ovarian stimulation protocols, judicious use of GnRH agonist triggers, and co-administration of cabergoline or low molecular weight heparin in high-risk patients. Supportive care for OHSS involves fluid management, thromboprophylaxis, and, in severe cases, hospitalization. Hypersensitivity reactions are managed with prompt drug discontinuation, antihistamines, corticosteroids, and, if needed, epinephrine. Multidisciplinary care, including reproductive endocrinologists, pharmacists, and maternal-fetal medicine specialists, is paramount for optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances in ART pharmacotherapy focus on reducing medication-related risks while maintaining efficacy. Introduction of long-acting gonadotropins, individualized dosing algorithms using AMH or antral follicle count, and antagonist protocols have lowered the incidence of OHSS. Emerging agents such as kisspeptin analogs for ovulation triggering and novel luteal phase support formulations are under investigation, aiming to further enhance safety profiles. The integration of pharmacogenomics into ART holds promise for predicting drug response and minimizing adverse events through personalized therapy.

Guideline Recommendations

International guidelines, including those from the American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE), advocate for comprehensive risk assessment prior to ART initiation. Recommendations emphasize individualized protocol selection, patient education on medication risks, prophylactic measures for high-risk individuals, and vigilant monitoring throughout the cycle. Guidelines also highlight the importance of reporting and tracking adverse events to inform continuous quality improvement in ART practice.

Conclusion

The expanding utilization of ART necessitates a thorough understanding of medication exposure risks and evidence-based strategies for risk mitigation. Clinicians must remain abreast of evolving pharmacological advances, individualized risk assessment tools, and guideline-directed management to ensure patient safety and optimize reproductive outcomes. Ongoing research and multidisciplinary collaboration are essential for refining ART protocols and enhancing the safety profile of assisted reproductive cycles.